V. Cambi

1.2k total citations
44 papers, 896 citations indexed

About

V. Cambi is a scholar working on Nephrology, Transplantation and Psychiatry and Mental health. According to data from OpenAlex, V. Cambi has authored 44 papers receiving a total of 896 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Nephrology, 12 papers in Transplantation and 8 papers in Psychiatry and Mental health. Recurrent topics in V. Cambi's work include Dialysis and Renal Disease Management (14 papers), Renal Transplantation Outcomes and Treatments (12 papers) and Neurological Complications and Syndromes (8 papers). V. Cambi is often cited by papers focused on Dialysis and Renal Disease Management (14 papers), Renal Transplantation Outcomes and Treatments (12 papers) and Neurological Complications and Syndromes (8 papers). V. Cambi collaborates with scholars based in Italy, United States and Switzerland. V. Cambi's co-authors include S. David, Giovanni Camussi, Luigi Biancone, Valentina Della Pietra, Giuseppe Montrucchio, Paolo Rigotti, Scott B. Campbell, Hélio Tedesco‐Silva, Valter Duro Garcı́a and Julio Pascual and has published in prestigious journals such as The Lancet, The Journal of Immunology and Kidney International.

In The Last Decade

V. Cambi

40 papers receiving 867 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
V. Cambi Italy 13 492 309 243 164 153 44 896
C F Barker United States 9 406 0.8× 342 1.1× 92 0.4× 122 0.7× 149 1.0× 19 729
J Lácha Czechia 17 346 0.7× 269 0.9× 263 1.1× 124 0.8× 42 0.3× 51 836
Shohei Fuchinoue Japan 18 424 0.9× 529 1.7× 248 1.0× 171 1.0× 56 0.4× 86 1.1k
Marisa Mir Spain 17 420 0.9× 289 0.9× 154 0.6× 148 0.9× 70 0.5× 46 828
Millie Samaniego United States 20 766 1.6× 474 1.5× 325 1.3× 124 0.8× 95 0.6× 32 1.1k
Hemangshu Podder United States 14 606 1.2× 459 1.5× 87 0.4× 98 0.6× 110 0.7× 37 910
G Civati Italy 16 582 1.2× 448 1.4× 106 0.4× 132 0.8× 151 1.0× 54 959
H. Prestele Germany 14 407 0.8× 273 0.9× 78 0.3× 195 1.2× 80 0.5× 42 982
Y Saint‐Hillier France 13 268 0.5× 115 0.4× 150 0.6× 111 0.7× 79 0.5× 35 558
Scott Ames United States 17 522 1.1× 500 1.6× 217 0.9× 254 1.5× 58 0.4× 33 1.3k

Countries citing papers authored by V. Cambi

Since Specialization
Citations

This map shows the geographic impact of V. Cambi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by V. Cambi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites V. Cambi more than expected).

Fields of papers citing papers by V. Cambi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by V. Cambi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by V. Cambi. The network helps show where V. Cambi may publish in the future.

Co-authorship network of co-authors of V. Cambi

This figure shows the co-authorship network connecting the top 25 collaborators of V. Cambi. A scholar is included among the top collaborators of V. Cambi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with V. Cambi. V. Cambi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cambi, V. & S. David. (2015). The Cost/Benefit Ratio of Renal Replacement Therapy. Contributions to nephrology. 109. 53–59.
2.
Tedesco‐Silva, Hélio, Š Vı́tko, Julio Pascual, et al.. (2006). 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients. Transplant International. 20(1). 27–36. 88 indexed citations
3.
Vı́tko, Š, Hélio Tedesco‐Silva, Josette Eris, et al.. (2004). Everolimus with Optimized Cyclosporine Dosing in Renal Transplant Recipients: 6-Month Safety and Efficacy Results of Two Randomized Studies. American Journal of Transplantation. 4(4). 626–635. 207 indexed citations
4.
Ponticelli, Claudio, V. Cambi, Christophe Legendre, et al.. (2001). A RANDOMIZED, DOUBLE-BLIND TRIAL OF BASILIXIMAB IMMUNOPROPHYLAXIS PLUS TRIPLE THERAPY IN KIDNEY TRANSPLANT RECIPIENTS1,2. Transplantation. 72(7). 1261–1267. 121 indexed citations
5.
Mignani, Renzo, et al.. (2001). Long-Term Survival of Patients with Renal Transplantation in Fabry�s Disease. Contributions to nephrology. 229–233. 8 indexed citations
6.
Montagnino, G., Antonio Tarantino, Giuseppe Segoloni, et al.. (2001). Long-Term Results of a Randomized Study Comparing Three Immunosuppressive Schedules with Cyclosporine in Cadaveric Kidney Transplantation. Journal of the American Society of Nephrology. 12(10). 2163–2169. 37 indexed citations
7.
Locatelli, Francesco, et al.. (2000). The management of chronic renal insufficiency in the conservative phase. Nephrology Dialysis Transplantation. 15(10). 1529–1534. 3 indexed citations
8.
Locatelli, Francesco, Fernando Valderrábano, Nicholas A. Hoenich, et al.. (2000). Progress in dialysis technology: membrane selection and patient outcome. Nephrology Dialysis Transplantation. 15(8). 1133–1139. 19 indexed citations
9.
Bussolati, Benedetta, Filippo Mariano, Luigi Biancone, et al.. (1999). Interleukin-12 Is Synthesized by Mesangial Cells and Stimulates Platelet-Activating Factor Synthesis, Cytoskeletal Reorganization, and Cell Shape Change. American Journal Of Pathology. 154(2). 623–632. 22 indexed citations
10.
Bussolati, Benedetta, Filippo Mariano, Alessandro Cignetti, et al.. (1998). Platelet-Activating Factor Synthesized by IL-12-Stimulated Polymorphonuclear Neutrophils and NK Cells Mediates Chemotaxis. The Journal of Immunology. 161(3). 1493–1500. 37 indexed citations
11.
Tarantino, A, Giuseppe Segoloni, V. Cambi, et al.. (1998). A randomized study comparing three cyclosporine-based regimens in cadaveric renal transplantation: results at 7 years. Transplantation Proceedings. 30(5). 1729–1731. 9 indexed citations
12.
Bignardi, L, et al.. (1997). Post-transplantation Kaposi's sarcoma appearing simultaneously in same cadaver donor renal transplant recipients. Nephrology Dialysis Transplantation. 12(5). 1055–1057. 11 indexed citations
13.
Ponticelli, Claudio, A Tarantino, Giuseppe Segoloni, et al.. (1997). A randomized study comparing cyclosporine alone vs double and triple therapy in renal transplants. Transplantation Proceedings. 29(1-2). 290–291. 14 indexed citations
14.
David, S., et al.. (1993). Production of Platelet Activating Factor by Human Neutrophils After Backfiltration of Endotoxin Contaminated Dialysate. ASAIO Journal. 39(3). M773–M777. 7 indexed citations
15.
David, S., et al.. (1991). The rôle of adsorption in beta 2-microglobulin removal.. PubMed. 6 Suppl 2. 64–8. 10 indexed citations
16.
David, S., et al.. (1989). Cyclosporin A and Drug Interaction. Advances in experimental medicine and biology. 252. 285–296. 2 indexed citations
17.
David, Stéphanie, et al.. (1989). Glucose Metabolism and Larger Molecule Removal in Long-Term High Efficiency Hemofiltration. Blood Purification. 7(1). 1–9. 3 indexed citations
18.
Rossi, Elisabetta, et al.. (1988). Partially Reversible Chronic Renal Failure Due to Long-term Use of Non-steroidal Anti-inflammatory Drugs. Nephrology Dialysis Transplantation. 3(4). 469–470. 1 indexed citations
19.
Bigi, Laura, et al.. (1979). Long-Term use of a “Stable” Bicarbonate Containing Dialysate. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 3(2-3). 119–134. 1 indexed citations
20.
Quadracci, Leonard J., et al.. (1971). Assay of serum abnormalities in uremic and dialysis patients. Evidence for depletion of vital substances in hemodialysis.. PubMed. 17. 96–101. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by C F Barker Breakdown of academic impact, for papers by J Lácha Breakdown of academic impact, for papers by Shohei Fuchinoue Breakdown of academic impact, for papers by Marisa Mir Breakdown of academic impact, for papers by Millie Samaniego Breakdown of academic impact, for papers by Hemangshu Podder Breakdown of academic impact, for papers by G Civati Breakdown of academic impact, for papers by H. Prestele Breakdown of academic impact, for papers by Y Saint‐Hillier Breakdown of academic impact, for papers by Scott Ames
Rankless by CCL
2026